Cargando…

Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis

The sympathetic nervous system (SNS) regulates host defense responses and restores homeostasis. SNS-immune regulation is altered in rheumatoid arthritis (RA) and rodent models of RA, characterized by nerve remodeling in immune organs and defective adrenergic receptor (AR) signaling to immune cell ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Lubahn, Cheri L., Lorton, Dianne, Schaller, Jill A., Sweeney, Sarah J., Bellinger, Denise L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127464/
https://www.ncbi.nlm.nih.gov/pubmed/25157248
http://dx.doi.org/10.3389/fimmu.2014.00346
_version_ 1782330028441206784
author Lubahn, Cheri L.
Lorton, Dianne
Schaller, Jill A.
Sweeney, Sarah J.
Bellinger, Denise L.
author_facet Lubahn, Cheri L.
Lorton, Dianne
Schaller, Jill A.
Sweeney, Sarah J.
Bellinger, Denise L.
author_sort Lubahn, Cheri L.
collection PubMed
description The sympathetic nervous system (SNS) regulates host defense responses and restores homeostasis. SNS-immune regulation is altered in rheumatoid arthritis (RA) and rodent models of RA, characterized by nerve remodeling in immune organs and defective adrenergic receptor (AR) signaling to immune cell targets. The SNS typically promotes or suppresses inflammation via α- and β(2)-AR activation, respectively, and indirectly drives humoral immunity by blocking Th1 cytokine secretion. Here, we investigate how β(2)-AR stimulation and/or α-AR blockade at disease onset affects disease pathology and cytokine profiles in relevant immune organs from male Lewis rats with adjuvant-induced arthritis (AA). Rats challenged to induce AA were treated with terbutaline (TERB), a β(2)-AR agonist (600 μg/kg/day) and/or phentolamine (PHEN), an α-AR antagonist (5.0 mg/kg/day) or vehicle from disease onset through severe disease. We report that in spleen, mesenteric (MLN) and draining lymph node (DLN) cells, TERB reduces proliferation, an effect independent of IL-2. TERB also fails to shift T helper (Th) cytokines from a Th1 to Th2 profile in spleen and MLN (no effect on IFN-γ) and DLN (greater IFN-γ) cells. In splenocytes, TERB, PHEN, and co-treatment (PT) promotes an anti-inflammatory profile (greater IL-10) and lowers TNF-α (PT only). In DLN cells, drug treatments do not affect inflammatory profiles, except PT, which raised IL-10. In MLN cells, TERB or PHEN lowers MLN cell secretion of TNF-α or IL-10, respectively. Collectively, our findings indicate disrupted β(2)-AR, but not α-AR signaling in AA. Aberrant β(2)-AR signaling consequently derails the sympathetic regulation of lymphocyte expansion, Th cell differentiation, and inflammation in the spleen, DLNs and MLs that is required for immune system homeostasis. Importantly, this study provides potential mechanisms through which reestablished balance between α- and β(2)-AR function in the immune system ameliorates inflammation and joint destruction in AA.
format Online
Article
Text
id pubmed-4127464
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41274642014-08-25 Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis Lubahn, Cheri L. Lorton, Dianne Schaller, Jill A. Sweeney, Sarah J. Bellinger, Denise L. Front Immunol Immunology The sympathetic nervous system (SNS) regulates host defense responses and restores homeostasis. SNS-immune regulation is altered in rheumatoid arthritis (RA) and rodent models of RA, characterized by nerve remodeling in immune organs and defective adrenergic receptor (AR) signaling to immune cell targets. The SNS typically promotes or suppresses inflammation via α- and β(2)-AR activation, respectively, and indirectly drives humoral immunity by blocking Th1 cytokine secretion. Here, we investigate how β(2)-AR stimulation and/or α-AR blockade at disease onset affects disease pathology and cytokine profiles in relevant immune organs from male Lewis rats with adjuvant-induced arthritis (AA). Rats challenged to induce AA were treated with terbutaline (TERB), a β(2)-AR agonist (600 μg/kg/day) and/or phentolamine (PHEN), an α-AR antagonist (5.0 mg/kg/day) or vehicle from disease onset through severe disease. We report that in spleen, mesenteric (MLN) and draining lymph node (DLN) cells, TERB reduces proliferation, an effect independent of IL-2. TERB also fails to shift T helper (Th) cytokines from a Th1 to Th2 profile in spleen and MLN (no effect on IFN-γ) and DLN (greater IFN-γ) cells. In splenocytes, TERB, PHEN, and co-treatment (PT) promotes an anti-inflammatory profile (greater IL-10) and lowers TNF-α (PT only). In DLN cells, drug treatments do not affect inflammatory profiles, except PT, which raised IL-10. In MLN cells, TERB or PHEN lowers MLN cell secretion of TNF-α or IL-10, respectively. Collectively, our findings indicate disrupted β(2)-AR, but not α-AR signaling in AA. Aberrant β(2)-AR signaling consequently derails the sympathetic regulation of lymphocyte expansion, Th cell differentiation, and inflammation in the spleen, DLNs and MLs that is required for immune system homeostasis. Importantly, this study provides potential mechanisms through which reestablished balance between α- and β(2)-AR function in the immune system ameliorates inflammation and joint destruction in AA. Frontiers Media S.A. 2014-08-11 /pmc/articles/PMC4127464/ /pubmed/25157248 http://dx.doi.org/10.3389/fimmu.2014.00346 Text en Copyright © 2014 Lubahn, Lorton, Schaller, Sweeney and Bellinger. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lubahn, Cheri L.
Lorton, Dianne
Schaller, Jill A.
Sweeney, Sarah J.
Bellinger, Denise L.
Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title_full Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title_fullStr Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title_full_unstemmed Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title_short Targeting α- and β-Adrenergic Receptors Differentially Shifts Th1, Th2, and Inflammatory Cytokine Profiles in Immune Organs to Attenuate Adjuvant Arthritis
title_sort targeting α- and β-adrenergic receptors differentially shifts th1, th2, and inflammatory cytokine profiles in immune organs to attenuate adjuvant arthritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127464/
https://www.ncbi.nlm.nih.gov/pubmed/25157248
http://dx.doi.org/10.3389/fimmu.2014.00346
work_keys_str_mv AT lubahncheril targetingaandbadrenergicreceptorsdifferentiallyshiftsth1th2andinflammatorycytokineprofilesinimmuneorganstoattenuateadjuvantarthritis
AT lortondianne targetingaandbadrenergicreceptorsdifferentiallyshiftsth1th2andinflammatorycytokineprofilesinimmuneorganstoattenuateadjuvantarthritis
AT schallerjilla targetingaandbadrenergicreceptorsdifferentiallyshiftsth1th2andinflammatorycytokineprofilesinimmuneorganstoattenuateadjuvantarthritis
AT sweeneysarahj targetingaandbadrenergicreceptorsdifferentiallyshiftsth1th2andinflammatorycytokineprofilesinimmuneorganstoattenuateadjuvantarthritis
AT bellingerdenisel targetingaandbadrenergicreceptorsdifferentiallyshiftsth1th2andinflammatorycytokineprofilesinimmuneorganstoattenuateadjuvantarthritis